NDAQ:QLGN - Post Discussion
Comment by
dmacd on Jun 25, 2019 2:00pm
RE:RE:Does Ritter Understand What is Has in RP-G28 ???
"The Company is further exploring the therapeutic potential that gut microbiome changes may have on treating/preventing a variety of diseases including gastrointestinal diseases, cancer, metabolic, and liver disease."
Read more at https://stockhouse.com/news/press-releases/2019/06/20/ritter-pharmaceuticals-provides-phase-3-liberatus-clinical-trial-and-regulatory#jM4T8Fl4MVFrIeTq.99
This is very promising. Liver disease prevention, healing or progression curbing will benefit from these therapeutics although a significant and rapid curation effect seems unlikely. I would like to see some lab tests with cure type approved or with advanced drug trials to see if there is a net benefit of Ritter and perhaps Immuron drugs. Ritter and Immuron can pay for the add-on experimentation provided there are financial terms, or reduce the efficacy based royalty and have the cure drug provider pay for the test work.
Due to cash flow constraints and share dilution these will have to happen once sales are more advanced unless a cure company provides a good deal for shareholders and management. We cannot afford to chase these opportunities right now with market placement dilution.
Almost time to load up in anticipation of Ph 3 results although perhaps the time will be when Ritter needs to raise cash to initiate NDA and early marketing. These stocks are ridiculously valued. The better strategy might be to do a deal with a suitable distributor as a non-exclusive or exclusive if milestones are achieved in anticipation of great results.
Interesting but ignored pharms ... strange markets ... huge upside for those that pan out if more dilution can be avoided that is.
Anyone know how many shares insiders own???
Be the first to comment on this post